Treatment of unresectable stage III NSCLC: Real world cohort study and literature review

Bray, 2018, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA. Cancer J. Clin., 68, 394, 10.3322/caac.21492 D. Planchard, S. Popat, K. Kerr, S. Novello, E.F. Smit, C. Faivre-Finn, T.S. Mok, M. Reck, P.E. Van Schil, M.D. Hellmann, Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up †, (2018). https://doi.org/10.1093/annonc/mdy275. Casal-Mouriño, 2021, Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival, Transl. Lung Cancer Res., 10, 506, 10.21037/tlcr.2020.03.40 Goldstraw, 2016, The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM Classification for lung cancer, J. Thorac. Oncol., 11, 39, 10.1016/j.jtho.2015.09.009 Choi, 2017, Application of the new 8th TNM staging system for non-small cell lung cancer: treated with curative concurrent chemoradiotherapy, Radiat. Oncol., 12, 122, 10.1186/s13014-017-0848-2 Aupérin, 2006, Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients, Ann. Oncol., 17, 473, 10.1093/annonc/mdj117 Aupérin, 2010, Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non - small-cell lung cancer, J. Clin. Oncol., 28, 2181, 10.1200/JCO.2009.26.2543 Bradley, 2015, Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial p, Lancet Oncol, 16, 187, 10.1016/S1470-2045(14)71207-0 Walraven, 2017, Treatment variation of sequential versus concurrent chemoradiotherapy in stage III non-small cell lung cancer patients in the Netherlands and Belgium, Clin. Oncol. (R. Coll. Radiol)., 29, e177, 10.1016/j.clon.2017.07.012 Mauguen, 2012, Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis, J. Clin. Oncol., 30, 2788, 10.1200/JCO.2012.41.6677 Senan, 2016, PROCLAIM: randomized Phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer, J. Clin. Oncol., 34, 953, 10.1200/JCO.2015.64.8824 Reck, 2016, Pembrolizumab versus chemotherapy for pd-l1-positive non-small-cell lung cancer, N. Engl. J. Med., 375, 1823, 10.1056/NEJMoa1606774 Rizzo, 2022, Identifying optimal first-line treatment for advanced non-small cell lung carcinoma with high PD-L1 expression: a matter of debate, Br. J. Cancer, 127, 1381, 10.1038/s41416-022-01929-w Viscardi, 2022, Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis, Eur. J. Cancer, 177, 175, 10.1016/j.ejca.2022.09.031 Antonia, 2017, Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer, N. Engl. J. Med., 377, 1919, 10.1056/NEJMoa1709937 Antonia, 2018, Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC, N. Engl. J. Med., 379, 2342, 10.1056/NEJMoa1809697 Gray, 2020, Three-year overall survival with durvalumab after chemoradiotherapy in stage III NSCLC—update from PACIFIC, J. Thorac. Oncol., 15, 288, 10.1016/j.jtho.2019.10.002 Faivre-Finn, 2021, Four-year survival with durvalumab after chemoradiotherapy in stage III NSCLC—an update from the PACIFIC trial, J. Thorac. Oncol., 16, 860, 10.1016/j.jtho.2020.12.015 Spigel, 2022, Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer, J. Clin. Oncol., 40, 1301, 10.1200/JCO.21.01308 Peters, 2019, Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer—The ETOP NICOLAS trial, Lung Cancer, 133, 83, 10.1016/j.lungcan.2019.05.001 van Diessen, 2019, The acute and late toxicity results of a randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial), Radiother. Oncol., 131, 166, 10.1016/j.radonc.2018.09.019 Mac Manus, 2001, High rate of detection of unsuspected distant metastases by PET in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy, Int. J. Radiat. Oncol. Biol. Phys., 50, 287, 10.1016/S0360-3016(01)01477-8 Bowden, 2017, Prediction of 90 day and overall survival after chemoradiotherapy for lung cancer: role of performance status and body composition, Clin. Oncol. (R. Coll. Radiol)., 29, 576, 10.1016/j.clon.2017.06.005 Ryan, 2019, Real-world outcomes in patients with unresected stage III non-small cell lung cancer, Med. Oncol., 36 Horinouchi, 2020, Real-world outcomes of chemoradiotherapy for unresectable stage III non-small cell lung cancer: the SOLUTION study, Cancer Med., 9, 6597, 10.1002/cam4.3306 Girard, 2021, Treatment strategies for unresectable locally advanced non-small cell lung cancer in the real-life ESME cohort, Lung Cancer, 162, 119, 10.1016/j.lungcan.2021.10.017 Jung, 2020, Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer, Lung Cancer, 146, 23, 10.1016/j.lungcan.2020.05.035 Lamberti, 2020, ALK and ROS1: current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma, Crit. Rev. Oncol. Hematol., 156 Cortiula, 2022, Immunotherapy in unresectable stage III non-small-cell lung cancer: state of the art and novel therapeutic approaches, Ann. Oncol. Off. J. Eur. Soc. Med. Oncol., 33, 893, 10.1016/j.annonc.2022.06.013